Roche announced today that it's division, known as Genentech, has produced positive results in a phase three EMILIA study of a drug called trastuzumab emtansine (T-DM1). Genentech says that the drug met the endpoint target for the trial, showing marked improvement for women with HER2-positive metastatic breast cancer...
More...